Development of Freeze-Dried Formulations for Biopharmaceutical Drug Products Using a Design of Experiments Approach: A Case Study on Antibody-Drug Conjugates.

The successful development of a lyophilized biopharmaceutical formulation relies on a systematic, science- and risk-based approach. By using a mock antibody-drug conjugate (ADC) as an example, this chapter outlines a structured pathway beginning with the definition of the quality target product profile (QTPP) and a thorough understanding of the active pharmaceutical ingredient's (API) physicochemical properties. Formulation components are selected based on their stabilization roles, guided by prior knowledge and literature, as well as a Design of Experiments (DoE methodology, which supports efficient screening of excipient combinations). An initial conservative freeze-drying cycle ensures stability of the API and drying efficiency. Analytical characterization, using techniques to detect critical quality attributes, which indicate stability and degradation of the API, enables the comparison of formulation candidates and the selection of a lead formulation. This lead formulation, paired with a well-designed initial freeze-drying process, serves as a solid foundation for further optimization within a quality by design (QbD) framework.